Four Keys To Successfully Launching AI In Life Sciences

Artificial intelligence (AI) has the potential to revolutionize how life sciences companies interact with patients, physicians, and the healthcare ecosystem as a whole. However, the road to successful AI implementation in the pharmaceutical industry is fraught with challenges, especially given the strict regulations, transparency requirements, and trust considerations that are non-negotiable in this field.

Many AI projects in pharma fall short of expectations, not due to technical limitations, but because the product strategy fails to account for the unique operational, scientific, and regulatory demands of the industry. Generic AI models like GPT-4 or Gemini, which work well in consumer tech, are ill-suited for pharma where content must undergo rigorous Medical-Legal-Regulatory (MLR) review before dissemination. Arpa Garay, former CMO at Merck and CCO at Moderna, emphasizes the need for purpose-built AI solutions that prioritize compliance, pre-approved content, and full audit trails to earn the trust of medical, legal, and regulatory teams.

While many AI developers focus on refining model inputs, compliance-focused AI products in pharma must ensure that outputs are also compliant. Repurposing general-purpose models for HCP communication or patient engagement risks noncompliant language and legal liabilities. Successful pharma AI initiatives employ closed-loop systems that exclusively present approved language, safeguarding brand reputation and ensuring compliance.

Achieving a balance between compliance and usability is crucial for AI adoption in healthcare. Jennifer Oleksiw, CCO at Eli Lilly, highlights the importance of responsible AI use and data capture methods to deliver personalized experiences to consumers. Pairing regulatory diligence with user-friendly design ensures that AI tools are not only compliant but also user-centric, enhancing decision-making and outcomes.

Enterprise-wide alignment is essential for the success of AI initiatives in pharma. Diogo Rau, CIO at Eli Lilly, emphasizes the need for cross-functional collaboration to address complex healthcare challenges effectively. Launching AI projects that address specific business or clinical needs, rather than following trends, is key to delivering measurable outcomes. Dalya Gayed, MD, VP & US marketing lead at Bristol Myers Squibb, stresses the importance of using AI to achieve tangible results in healthcare, not just for the sake of innovation.

In conclusion, the future of AI in the life sciences industry lies in a strategic, context-aware approach that prioritizes compliance, usability, and tangible outcomes. Companies that successfully navigate the intersection of innovation, regulation, and user needs will lead the transformation of healthcare through AI.